GlassScriptPhysician profile
Leila M Youssef
NPI 1629071550
$11,743.58
in general payments reported to CMS, 2019-2025
46 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,353 · 2020: $1,138 · 2021: $1,966 · 2022: $1,675 · 2023: $2,206 · 2024: $2,257 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,610.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,684.02 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,452.21 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $1,034.10 | 2019-2025 | |
| Novo Nordisk INC | $940.35 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $774.07 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $770.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $696.41 | 2019-2025 | Otezla, Repatha, Evenity |
| Merck Sharp & Dohme LLC | $576.43 | 2019-2025 | Verquvo, Capvaxive, Belsomra |
| Esperion Therapeutics, INC. | $376.37 | 2020-2024 | Nexletol |
| Gilead Sciences, INC. | $373.75 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $299.47 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.93 | 2019-2025 | Jardiance |
| Horizon Therapeutics Plc | $232.30 | 2021-2023 | Krystexxa |
| Amarin Pharma, INC. | $220.26 | 2019-2022 | |
| Astellas Pharma US INC | $203.68 | 2022-2025 | Veozah |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leila Youssef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.